학술논문

Abietane-Type Diterpenoids Inhibit Protein Tyrosine Phosphatases by Stabilizing an Inactive Enzyme Conformation
Document Type
article
Source
Biochemistry. 57(40)
Subject
Biochemistry and Cell Biology
Medicinal and Biomolecular Chemistry
Chemical Sciences
Biological Sciences
5.1 Pharmaceuticals
Development of treatments and therapeutic interventions
Generic health relevance
Abietanes
Humans
Models
Molecular
Molecular Dynamics Simulation
Nuclear Magnetic Resonance
Biomolecular
Protein Domains
Protein Folding
Protein Kinase Inhibitors
Protein Tyrosine Phosphatase
Non-Receptor Type 1
Medical Biochemistry and Metabolomics
Biochemistry & Molecular Biology
Biochemistry and cell biology
Medical biochemistry and metabolomics
Medicinal and biomolecular chemistry
Language
Abstract
Protein tyrosine phosphatases (PTPs) contribute to a striking variety of human diseases, yet they remain vexingly difficult to inhibit with uncharged, cell-permeable molecules; no inhibitors of PTPs have been approved for clinical use. This study uses a broad set of biophysical analyses to evaluate the use of abietane-type diterpenoids, a biologically active class of phytometabolites with largely nonpolar structures, for the development of pharmaceutically relevant PTP inhibitors. Results of nuclear magnetic resonance analyses, mutational studies, and molecular dynamics simulations indicate that abietic acid can inhibit protein tyrosine phosphatase 1B, a negative regulator of insulin signaling and an elusive drug target, by binding to its active site in a non-substrate-like manner that stabilizes the catalytically essential WPD loop in an inactive conformation; detailed kinetic studies, in turn, show that minor changes in the structures of abietane-type diterpenoids (e.g., the addition of hydrogens) can improve potency (i.e., lower IC50) by 7-fold. These findings elucidate a previously uncharacterized mechanism of diterpenoid-mediated inhibition and suggest, more broadly, that abietane-type diterpenoids are a promising source of structurally diverse-and, intriguingly, microbially synthesizable-molecules on which to base the design of new PTP-inhibiting therapeutics.